Superluminal Medicines Inc.
Murco Ringnalda currently serves as the Senior Vice President and Head of Operations at Superluminal Medicines Inc since July 2023. Prior to this role, Murco Ringnalda had a tenure at Schrödinger, Inc. from April 1991 to September 2020, where various positions were held. Educational qualifications include a Bachelor of Arts from Reed College, a Ph.D. in Chemistry from The University of Texas at Austin, and an M.B.A. from the University of Oregon.
This person is not in any teams
This person is not in any offices
Superluminal Medicines Inc.
Superluminal Medicines is a Boston-based generative biology and chemistry company developing a differentiated pipeline and revolutionizing the speed and accuracy of how medicine is created. Our platform creates candidate-ready compounds with unprecedented speed using a comprehensive combination of deep biology and chemistry expertise, machine learning, and proprietary big data infrastructure. The predict-design-test architecture accurately models protein shapes and designs highly selective compounds to target the precise structural change for therapeutic effect. Our discovery engine is powered by an industry-leading, pharmacokinetic and toxicology in silico prediction capability. With a lead program candidate expected in the near term, our proprietary pipeline validates our platform with initial programs focused on high-value GPCR targets. We’re pleased to be backed by a strong network of investors including RA Capital Management, Insight Partners, NVIDIA and Gaingels.